Evidence map›Paper›PMID 33603169›Full record

ArticleOncogene2021

HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner.

Busra Turgu, Fan Zhang, Amal El-Naggar, Gian Luca Negri, Melanie Kogler, Luigi Tortola, Fraser Johnson, Tony Ng, Amy Li, Donald Yapp and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 5 countries.

Busra Turgu *Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada.
Fan Zhang *Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Amal El-NaggarDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada.
Gian Luca NegriCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-7722-8888
Melanie KoglerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
Luigi TortolaInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-8480-2080
Fraser JohnsonDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada.
Tony NgDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Amy LiDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada.
Donald YappDepartment of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
William LockwoodDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Daniel MartinezDepartment of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, USA.ORCID http://orcid.org/0000-0002-8088-7929
Mads DaugaardDepartment of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.ORCID http://orcid.org/0000-0002-8194-3777
Christopher S HughesDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada.
Poul H SorensenDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, Canada. psor@mail.ubc.ca.ORCID http://orcid.org/0000-0001-7447-2199
University of British Columbia · CAInstitute of Molecular Biotechnology · ATChildren's Hospital of Philadelphia · USBC Cancer Agency · CACanada's Michael Smith Genome Sciences Centre · CAUniversity of British Columbia Hospital · CA

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 377771
6 · The paper itself

Abstract

Uncovering the mechanisms that underpin how tumor cells adapt to microenvironmental stress is essential to better understand cancer progression. The HACE1 (HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase) gene is a tumor suppressor that inhibits the growth, invasive capacity, and metastasis of cancer cells. However, the direct regulatory pathways whereby HACE1 confers this tumor-suppressive effect remain to be fully elucidated. In this report, we establish a link between HACE1 and the major stress factor, hypoxia-inducible factor 1 alpha (HIF1α). We find that HACE1 blocks the accumulation of HIF1α during cellular hypoxia through decreased protein stability. This property is dependent on HACE1 E3 ligase activity and loss of Ras-related C3 botulinum toxin substrate 1 (RAC1), an established target of HACE1 mediated ubiquitinylation and degradation. In vivo, genetic deletion of Rac1 reversed the increased HIF1α expression observed in Hace1

Indexed as

AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitLung NeoplasmsMiceMice, KnockoutNeoplasm MetastasisProtein Stabilityrac1 GTP-Binding ProteinSignal TransductionTumor HypoxiaTumor Suppressor ProteinsUbiquitinationUbiquitin-Protein LigasesHACE1 protein, humanHACE1 protein, mouseHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunitrac1 GTP-Binding ProteinRAC1 protein, humanTumor Suppressor ProteinsUbiquitin-Protein Ligases

Identifiers

PMID33603169
PMCPMC7979542
OpenAlexW3133283630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.